Disproportionality analysis of progestogens and estrogens demonstrates increased meningioma risk

IF 1.9 4区医学 Q3 CLINICAL NEUROLOGY

Journal of Clinical Neuroscience Pub Date : 2025-05-16 DOI:10.1016/j.jocn.2025.111328

Connor Frey , Mahyar Etminan

{"title":"Disproportionality analysis of progestogens and estrogens demonstrates increased meningioma risk","authors":"Connor Frey , Mahyar Etminan","doi":"10.1016/j.jocn.2025.111328","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>This study aims to clarify the relationship between the use of various progestogens and estrogens and the risk of developing meningiomas, given the widespread prescription of hormonal contraceptives and their potential implications in tumour proliferation.</div></div><div><h3>Methods</h3><div>Data from the FDA Adverse Event Reporting System (FAERS) was analyzed using disproportionality analysis to assess the association between specific progestogens and estrogens and meningioma risk. Reporting odds ratios (RORs) and 95% confidence intervals (CIs) were calculated to quantify these associations.</div></div><div><h3>Results</h3><div>Among progestogens, promegestone showed the highest risk with an ROR of 2620.651 (95% CI: 982.032, 6993.474), followed by medrogestone with an ROR of 871.475 (95% CI: 256.382, 2962.253) and dydrogesterone with moderate risk (ROR 113.802; 95% CI: 60.676, 213.444). For estrogens, estradiol exhibited the highest risk (ROR 17.786; 95% CI: 14.875, 21.266), followed by ethinyl estradiol (ROR 7.441; 95% CI: 6.099, 9.080), while conjugated estrogens showed a lower risk (ROR 1.736; 95% CI: 1.043, 2.889). No cases were reported for estriol, estrone, or mestranol, indicating a potentially lower risk profile for these estrogens.</div></div><div><h3>Conclusion</h3><div>The study reveals significant variations in meningioma risk associated with different hormonal therapies. Certain progestogens and estrogens present notably higher risks, emphasizing the need for personalized risk assessments in hormonal therapy prescriptions. These findings advocate for further research to better understand meningioma risk linked to hormone-based contraceptives, supporting safer clinical decision-making.</div></div>","PeriodicalId":15487,"journal":{"name":"Journal of Clinical Neuroscience","volume":"137 ","pages":"Article 111328"},"PeriodicalIF":1.9000,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Neuroscience","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0967586825003005","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

This study aims to clarify the relationship between the use of various progestogens and estrogens and the risk of developing meningiomas, given the widespread prescription of hormonal contraceptives and their potential implications in tumour proliferation.

Methods

Data from the FDA Adverse Event Reporting System (FAERS) was analyzed using disproportionality analysis to assess the association between specific progestogens and estrogens and meningioma risk. Reporting odds ratios (RORs) and 95% confidence intervals (CIs) were calculated to quantify these associations.

Results

Among progestogens, promegestone showed the highest risk with an ROR of 2620.651 (95% CI: 982.032, 6993.474), followed by medrogestone with an ROR of 871.475 (95% CI: 256.382, 2962.253) and dydrogesterone with moderate risk (ROR 113.802; 95% CI: 60.676, 213.444). For estrogens, estradiol exhibited the highest risk (ROR 17.786; 95% CI: 14.875, 21.266), followed by ethinyl estradiol (ROR 7.441; 95% CI: 6.099, 9.080), while conjugated estrogens showed a lower risk (ROR 1.736; 95% CI: 1.043, 2.889). No cases were reported for estriol, estrone, or mestranol, indicating a potentially lower risk profile for these estrogens.

Conclusion

The study reveals significant variations in meningioma risk associated with different hormonal therapies. Certain progestogens and estrogens present notably higher risks, emphasizing the need for personalized risk assessments in hormonal therapy prescriptions. These findings advocate for further research to better understand meningioma risk linked to hormone-based contraceptives, supporting safer clinical decision-making.

查看原文本刊更多论文

孕激素和雌激素的不成比例分析显示脑膜瘤风险增加

目的：考虑到激素避孕药的广泛使用及其对肿瘤增殖的潜在影响，本研究旨在阐明各种孕激素和雌激素的使用与脑膜瘤发生风险之间的关系。方法对FDA不良事件报告系统（FAERS）的数据进行歧化分析，评估特定孕激素和雌激素与脑膜瘤风险的关系。计算报告优势比（RORs）和95%置信区间（ci）来量化这些关联。结果孕激素中，孕酮风险最高，ROR为2620.651 (95% CI: 982.032, 6993.474)，其次是甲孕酮，ROR为871.475 (95% CI: 256.382, 2962.253)，地孕酮风险中等(ROR为113.802；95% ci: 60.676, 213.444)。雌激素中，雌二醇风险最高(ROR 17.786；95% CI: 14.875, 21.266)，其次是乙炔雌二醇(ROR 7.441；95% CI: 6.099, 9.080)，而结合雌激素的风险较低(ROR为1.736；95% ci: 1.043, 2.889)。没有雌三醇、雌酮或美雌醇的病例报告，表明这些雌激素的潜在风险较低。结论不同激素治疗对脑膜瘤发病风险有显著影响。某些孕激素和雌激素的风险明显更高，强调了在激素治疗处方中进行个性化风险评估的必要性。这些发现提倡进一步研究，以更好地了解与激素避孕药相关的脑膜瘤风险，支持更安全的临床决策。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Clinical Neuroscience 医学-临床神经学

CiteScore

4.50

自引率

0.00%

发文量

402

审稿时长

40 days

期刊介绍： This International journal, Journal of Clinical Neuroscience, publishes articles on clinical neurosurgery and neurology and the related neurosciences such as neuro-pathology, neuro-radiology, neuro-ophthalmology and neuro-physiology. The journal has a broad International perspective, and emphasises the advances occurring in Asia, the Pacific Rim region, Europe and North America. The Journal acts as a focus for publication of major clinical and laboratory research, as well as publishing solicited manuscripts on specific subjects from experts, case reports and other information of interest to clinicians working in the clinical neurosciences.